Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018; 20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Judgmentalism applied to patients from poor and marginalized communities exacerbates health inequity and illuminates the importance of contextualizing a patient’s care.
AMA J Ethics. 2021; 23(2):E91-96. doi:
10.1001/amajethics.2021.91.